Resources

Centre

~70^%

of patients with ALK+ NSCLC have never smoked^3–6

>50^%

 of patients with ALK+ NSCLC are younger than 60   years⁷

~30^%

 of patients with ALK+ NSCLC have baseline CNS   metastasis at diagnosis^3,5,7

>50^%

 50% of patients with ALK+ mNSCLC receiving   crizotinib progress within 1 year¹

>50^%

 of patients with ALK+ mNSCLC receiving crizotinib   will not live past 5 years¹